Checkpoint blockade antibodies targeting programmed cell-death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have shown great promise in the clinic, causing complete tumor regression and durable responses in a segment of patients [2, 3]. Here, CD274 is linked to neoplasm.